Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8386 to 8400 of 9030 results

  1. Nivolumab for treating relapsed or refractory diffuse large B-cell lymphoma [ID986]

    Discontinued Reference number: GID-TA10140

    Technology appraisal guidance
    Discontinued

  2. Everolimus with exemestane for treating HER2-negative hormone-receptor-positive breast cancer after endocrine therapy [ID965]

    Discontinued Reference number: GID-TA10028

    Technology appraisal guidance
    Discontinued

  3. Clofarabine for treating acute lymphoblastic leukaemia in children after 2 therapies [ID1033]

    Discontinued Reference number: GID-TA10081

    Technology appraisal guidance
    Discontinued

  4. Nelarabine for treating refractory T-cell lymphoblastic non-Hodgkin's lymphoma [ID1044]

    Discontinued Reference number: GID-TA10087

    Technology appraisal guidance
    Discontinued

  5. Nelarabine for treating acute lymphoblastic leukaemia after two therapies [ID1034]

    Discontinued Reference number: GID-TA10088

    Technology appraisal guidance
    Discontinued

  6. Pertuzumab for untreated metastatic HER2-positive gastric or gastro-oesophageal junction cancer [ID1096]

    Discontinued Reference number: GID-TA10159

    Technology appraisal guidance
    Discontinued

  7. Sirukumab for previously treated moderate to severe active rheumatoid arthritis (ID1002)

    Discontinued Reference number: GID-TA10180

    Technology appraisal guidance
    Discontinued

  8. Nivolumab with ipilimumab for previously treated extensive stage small-cell lung cancer [ID1228]

    Discontinued Reference number: GID-TA10203

    Technology appraisal guidance
    Discontinued

  9. Pembrolizumab for previously treated metastatic gastric or gastro-oesophageal junction cancer [ID1168]

    Discontinued Reference number: GID-TA10208

    Technology appraisal guidance
    Discontinued

  10. Avelumab for treating gastric or gastro-oesophageal junction cancer after 2 therapies ID1289

    Discontinued Reference number: GID-TA10210

    Technology appraisal guidance
    Discontinued

  11. Venetoclax with ibrutinib and obinutuzumab for untreated chronic lymphocytic leukaemia ID1270

    Discontinued Reference number: GID-TA10211

    Technology appraisal guidance
    Discontinued

  12. Nivolumab in combination with platinum-doublet chemotherapy for untreated non-small-cell lung cancer [ID1135]

    Discontinued Reference number: GID-TA10233

    Technology appraisal guidance
    Discontinued

  13. Dapagliflozin, empagliflozin and sotagliflozin for treating type 1 diabetes [ID1217]

    Discontinued Reference number: GID-TA10236

    Technology appraisal guidance
    Discontinued

  14. Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant [ID1103]

    Discontinued Reference number: GID-TA10144

    Technology appraisal guidance
    Discontinued

  15. Nivolumab monotherapy for non-small-cell lung cancer [ID1088]

    Discontinued Reference number: GID-TA10148

    Technology appraisal guidance
    Discontinued